Apellis Pharmaceuticals, Inc. (APLS) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2026
Loading P/E history...
APLS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
The current P/E is 166% above its 5-year average of 85.5x. Over the past five years, APLS's P/E has ranged from a low of 44.2x to a high of 147.8x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, APLS trades at a 921% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, APLS commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our APLS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
APLS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9 | 0.67 | +817%Best | |
| $74B | 17.1 | 2.70 | +8% | |
| $28B | 21.7 | - | -21% | |
| $5B | 16.7 | 0.44Best | +8% | |
| $213M | 1.2Lowest | - | +472% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
APLS Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $40.23 | $0.91 | 44.2x | -48% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $25.12 | $0.17 | 147.8x | +73% |
| FY2025 Q3 | $22.63 | $0.35 | 64.7x | -24% |
Average P/E for displayed period: 85.5x
See APLS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APLS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APLS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAPLS — Frequently Asked Questions
Quick answers to the most common questions about buying APLS stock.
Is APLS stock overvalued or undervalued?
APLS trades at 227.8x P/E, above its 5-year average of 85.5x. The 100th percentile ranking indicates a premium to historical valuation.
How does APLS's valuation compare to peers?
Apellis Pharmaceuticals, Inc. P/E of 227.8x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is APLS's PEG ratio?
APLS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2026.